Future studies should focus on whether silencing of STAT3 expression using STAT3 shRNA or its inhibitor such as non-receptor tyrosine kinase is useful as a novel adjuvant therapy to chemotherapy for pancreatic cancer patients. Here, NTRK1 is linked to familial pancreatic carcinoma.